Jan 2026 ANVISA GMP renewed for Tarapur facility Read more

Privacy

This site tracks nothing by default.

new.naprodgroup.com ships with zero tracking cookies, zero third-party analytics scripts, and zero advertising pixels at launch. The only personal data collected is what a visitor types into a form and chooses to submit.

0 tracking cookies at launch · 0 third-party analytics scripts · GDPR-aware for EU visitors

What this site collects

Only what a visitor submits, nowhere else

new.naprodgroup.com does not set tracking or advertising cookies, does not run third-party analytics scripts, and does not build a profile of any visitor. The only personal data the site receives is what a visitor voluntarily types into a form — a name, an email address, an organization, and a message — when contacting Naprod, applying to a posted role, or submitting a pharmacovigilance or product-quality report. No data is collected simply by browsing the site.

Pending approval The receiving mailbox, retention period, and named Data Protection Officer for form submissions are pending confirmation from Naprod's legal and IT teams and are shown as PENDING APPROVAL until published.

Cookies

No consent banner, because there is nothing to consent to

This site does not use tracking cookies, analytics cookies, or advertising cookies, so it does not display a cookie-consent banner. Astro's static hosting layer (Azure Static Web Apps) may set a small number of strictly necessary technical cookies required to serve the site securely; none of these identify a visitor, track behavior across sessions, or leave the hosting infrastructure. If that changes at a future stage — for example, if analytics are added — this policy and a consent mechanism will be updated before any such cookie is set.

GDPR

For visitors in the European Union

Naprod expects visitors from the European Union, given its EU-GMP export relationships, and treats form submissions from EU visitors under the EU General Data Protection Regulation (GDPR). Any personal data submitted through a form on this site — a contact enquiry, a job application, or a pharmacovigilance report — is processed only for the purpose it was submitted for, is not sold or shared with third parties for marketing, and is retained only as long as needed to handle that enquiry, respond to a regulatory obligation, or comply with applicable pharmacovigilance record-keeping requirements. EU visitors have the right to request access to, correction of, or deletion of personal data they have submitted, and to lodge a complaint with their national supervisory authority.

Pending approval The named EU representative or Data Protection Officer contact point, and the specific retention periods per submission type, are pending legal confirmation and are shown as PENDING APPROVAL until verified.

Product-information disclaimer

This site does not provide medical or prescribing information

Naprod manufactures oncology, anesthesia, and critical-care injectables for healthcare professionals, distributors, and regulatory affairs contacts — not for patients seeking treatment guidance. Nothing on this site constitutes medical advice, a claim of therapeutic efficacy, or prescribing information for any product. Product listings on this site describe manufacturing and regulatory-dossier status only. Healthcare professionals and patients should direct all clinical, dosing, and treatment questions to a qualified physician or pharmacist, and should report any suspected adverse event or product-quality complaint through the pharmacovigilance pathway on the Contact page rather than through this policy.

Questions about this policy

How to reach us

Questions about what data this site collects, requests to access or delete personal data submitted through a form, and pharmacovigilance or product-quality reports can all be directed through the Contact page. Naprod will confirm a dedicated privacy contact and, where GDPR requires it, an EU representative, as part of finalizing this policy ahead of go-live.

Pending approval Dedicated privacy-request email address and EU representative contact are pending confirmation and are shown as PENDING APPROVAL until published.